Investigating the links between retinopathy, macular edema and visual acuity in patients with diabetes

Expert Review of Ophthalmology

Volumn 3, Issue 6, 2008, Pages 673-688

  Tucker, Daniel ^a   Rousculp, Matt ^b   Girach, Aniz ^b   Palmer, Andrew ^a   Valentine, William ^a  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetic retinopathy; Incidence; Macular edema; Prevalence; Visual acuity

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; RANIBIZUMAB; RUBOXISTAURIN;

AUSTRALIA; BLINDNESS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; EUROPE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; UNITED KINGDOM; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 70049118328     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.6.673     Document Type: Review

References (175)

1. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab. Rev. 5(7), 559-570 (1989).
2. National Society to Prevent Blindness. Vision Problems in the US: Facts and Figures. National Society to Prevent Blindness, NY, USA (1980).
3. Younis N, Broadbent DM, Harding SP, Vora JR. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabet. Med. 19(12), 1014-1021 (2002).
4. Skrivarhaug T, Fosmark DS, Stene LC et al. Low cumulative incidence of proliferative retinopathy in childhood-onset Type 1 diabetes: a 24-year follow-up study. Diabetologia 49(10), 2281-2290 (2006).
5. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes - the Linkoping Diabetes Complications Study. Diabetologia 47(7), 1266-1272 (2004).
6. Hovind P, Tarnow L, Rossing K et al. Decreasing incidence of severe diabetic microangiopathy in Type 1 diabetes. Diabetes Care 26(4), 1258-1264 (2003).
7. Henricsson M, Nystrom L, Blohme G et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26(2), 349-354 (2003).
8. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye 21(4), 465-471 (2007).
9. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with Type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361(9353), 195-200 (2003).
10. Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44(2), 156-163 (2001).
11. Bamashmus MA, Matlhaga B, Dutton GN. Causes of blindness and visual impairment in the West of Scotland. Eye 18(3), 257-261 (2004).
12. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 6, 58 (2006).
13. Kelliher C, Kenny D, O'Brien C. Trends in blind registration in the adult population of the Republic of Ireland 1996-2003. Br. J. Ophthalmol. 90(3), 367-371 (2006).
14. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm. 60, 149-193 (2000).
15. West SK, Klein R, Rodriguez J et al. Diabetes and diabetic retinopathy in a Mexican - American population: Proyecto VER. Diabetes Care 24(7), 1204-1209 (2001).
16. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch. Ophthalmol. 113(1), 36-51. (1995).
17. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in Type 2 diabetes mellitus: UKPDS 69. Arch. Ophthalmol. 122(11), 1631-1640 (2004).
18. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317, 703-713 (1998).
19. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care 23(Suppl. 2), B54-B64 (2000).
20. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102(1), 7-16 (1995).
21. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in Type 1 diabetes. Ophthalmology 105(10), 1801-1815 (1998).
22. Chew EY, Ferris FL, III, Csaky KG et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 110(9), 1683-1689 (2003).
23. Chew EY, Klein ML, Ferris FL et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 114(9), 1079-1084 (1996).
24. Broman AT, Munoz B, Rodriguez J et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest. Ophthalmol. Vis. Sci. 43(11), 3393-3398 (2002).
25. Swanson MW, McGwin G. Visual impairment and functional status from the 1995 National Health Interview Survey on Disability. Ophthalmic Epidemiol. 11(3), 227-239 (2004).
26. Klein BE, Klein R, Lee KE, Cruickshanks KJ. Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study. Ophthalmology 105(1), 160-164 (1998).
27. West SK, Munoz B, Rubin GS et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. Invest. Ophthalmol. Vis. Sci. 38(1), 72-82 (1997).
28. Dargent-Molina P, Favier F, Grandjean H et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 348(9021), 145-149 (1996).
29. Felson DT, Anderson JJ, Hannan MT, Milton RC, Wilson PW, Kiel DP. Impaired vision and hip fracture. The Framingham Study. J. Am. Geriatr. Soc. 37(6), 495-500 (1989).
30. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J. Am. Geriatr. Soc. 46(1), 58-64 (1998).
31. Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am. J. Epidemiol. 152(7), 633-639 (2000).
32. Tsai SY, Cheng CY, Hsu WM, Su TP, Liu JH, Chou P. Association between visual impairment and depression in the elderly. J. Formos. Med. Assoc. 102(2), 86-90 (2003).
33. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol. 103(12), 1796-1806 (1985).
34. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol. Scand. 77(2), 170-175 (1999).
35. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 91(1), 1-9 (1984).
36. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD. Prevalence and significance of retinopathy in subjects with Type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 24(3), 522-526 (2001).
37. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican - Americans than in non-Hispanic whites with Type 2 diabetes? A U.S. population study. Diabetes Care 21(8), 1230-1235 (1998).
38. Chaturvedi N, Jarrett J, Shipley MJ, Fuller JH. Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall Study and the WHO Multinational Study of Vascular Disease in Diabetes. BMJ 316(7125), 100-105 (1998).
39. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care 19(5), 423-430 (1996).
40. Connolly VM, Kesson CM. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Diabetes Care 19(5), 419-422 (1996).
41. Harris MI. Racial and ethnic differences in health insurance coverage for adults with diabetes. Diabetes Care 22(10), 1679-1682 (1999).
42. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA 279(21), 1703-1708 (1998).
43. Mayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med. Care Res. Rev. 57(Suppl. 1), 108-145 (2000).
44. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Excess Type 2 diabetes in African - American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey. J. Epidemiol. Community Health 54(11), 839-845 (2000).
45. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 287(10), 1288-1294 (2002).
46. Wagstaff A, van Doorslaer E. Income inequality and health: what does the literature tell us? Annu. Rev. Public Health 21, 543-567 (2000).
47. Henricsson M, Heijl A. Visual fields at different stages of diabetic retinopathy. Acta Ophthalmol. (Copenh.) 72(5), 560-569 (1994).
48. Henricsson M, Sellman A, Tyrberg M, Groop L. Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol. Scand. 77(2), 218-223 (1999).
49. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch. Ophthalmol. 113(9), 1144-1155 (1995).
50. Fong DS, Sharza M, Chen W, Paschal JF, Ariyasu RG, Lee PP. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am. J. Ophthalmol. 133(2), 236-241 (2002).
51. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, Cathelineau G, Papoz L; CODIAB-INSERM-ZENECA Pharma Study Group. Visual impairment in Type 2 diabetic patients. A multicentre study in France. Acta Ophthalmol. Scand. 73(4), 293-298 (1995).
52. Zander E, Herfurth S, Bohl B et al. Maculopathy in patients with diabetes mellitus Type 1 and Type 2: associations with risk factors. Br. J. Ophthalmol. 84(8), 871-876 (2000).
53. Kohner EM, Aldington SJ, Stratton IM et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch. Ophthalmol. 116(3), 297-303 (1998).
54. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br. J. Ophthalmol. 87(1), 8-12 (2003).
55. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br. J. Ophthalmol. 90(3), 272-275 (2006).
56. Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. J. Epidemiol. Community Health 52(1), 45-52 (1998).
57. Legorreta AP, Hasan MM, Peters AL, Pelletier KR, Leung KM. An intervention for enhancing compliance with screening recommendations for diabetic retinopathy. A bicoastal experience. Diabetes Care 20(4), 520-523 (1997).
58. Moss SE, Klein R, Klein BE. Factors associated with having eye examinations in persons with diabetes. Arch. Fam Med. 4(6), 529-534 (1995).
59. Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 108(3), 563-571 (2001).
60. McCarty CA, Taylor KI, McKay R, Keeffe JE. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin. Experiment. Ophthalmol. 29(2), 52-58 (2001).
61. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
62. Buckley S, Jenkins L, Benjamin L. Field loss after pan retinal photocoagulation with diode and argon lasers. Doc. Ophthalmol. 82(4), 317-322. (1992).
63. Buckley SA, Jenkins L, Benjamin L. Fields, DVLC and panretinal photocoagulation. Eye 6(Pt 6), 623-625 (1992).
64. Canning C, Polkinghorne P, Ariffin A, Gregor Z. Panretinal laser photocoagulation for proliferative diabetic retinopathy: the effect of laser wavelength on macular function. Br. J. Ophthalmol. 75(10), 608-610 (1991).
65. Friberg TR, Venkatesh S. Alteration of pulse configuration affects the pain response during diode laser photocoagulation. Lasers Surg. Med. 16(4), 380-383. (1995).
66. Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation. Int. Ophthalmol. 22(5), 313-319 (1998).
67. Patel JI, Jenkins L, Benjamin L, Webber S. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases. Eye 16(5), 628-632 (2002).
68. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22(2), 143-152 (2002).
69. Girach A, Aiello LP, Vignati L et al. Effect of the oral PKC inhibitor ruboxistaurin on vision loss in patients with diabetic retinopathy: The PKC-DRS2 Study Results. Eur. J. Ophthalmol. 16(3), 500 (2006).
70. Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109(5), 920-927 (2002).
71. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341(2-3), 309-315 (1998).
72. Haritoglou C, Kook D, Neubauer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26(9), 999-1005 (2006).
73. Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 28(8), 1053-1060 (2008).
74. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18(10), 963-983 (2004).
75. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21(9), 1414-1431 (1998).
76. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29(6), 1263-1268 (2006).
77. Rosenberg EA, Sperazza LC. The visually impaired patient. Am. Fam. Physician 77(10), 1431-1436 (2008).
78. Kristinsson JK, Hauksdottir H, Stefansson E, Jonasson F, Gislason I. Active prevention in diabetic eye disease. A 4-year follow-up. Acta Ophthalmol. Scand. 75(3), 249-254 (1997).
79. Aiello LP, Gardner TW, King GL et al. Diabetic retinopathy. Diabetes Care 21(1), 143-156 (1998).
80. Backlund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet. Med. 14(9), 732-740 (1997).
81. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol. Scand. 78(4), 374-385 (2000).
82. Zoega GM, Gunnarsdottir T, Bjornsdottir S, Hreietharsson AB, Viggosson G, Stefansson E. Screening compliance and visual outcome in diabetes. Acta Ophthalmol. Scand. 83(6), 687-690 (2005).
83. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann. Intern. Med. 124(1 Pt2), 164-169 (1996).
84. Vitale S, Maguire MG, Murphy RP et al. Clinically significant macular edema in Type I diabetes. Incidence and risk factors. Ophthalmology 102(8), 1170-1176 (1995).
85. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 107(2), 237-243 (1989).
86. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch. Ophthalmol. 107(2), 244-249 (1989).
87. Benson WH, Farber ME. Diabetic retinopathy in a rural diabetic population. Prevalence and risk. WV Med. J. 85(4), 141-143 (1989).
88. Berinstein DM, Stahn RM, Welty TK, Leonardson GR, Herlihy JJ. The prevalence of diabetic retinopathy and associated risk factors among Sioux Indians. Diabetes Care 20(5), 757-759 (1997).
89. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes 38(10), 1231-1237 (1989).
90. Kempen JH, O'Colmain BJ, Leske MC et al. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 122(4), 552-563 (2004).
91. Klein R, Davis MD, Moss SE, Klein BE, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. A comparison of retinopathy in younger and older onset diabetic persons. Adv. Exp. Med. Biol. 189, 321-335 (1985).
92. Klein R, Klein BE, Moss SE. A population-based study of diabetic retinopathy in insulin-using patients diagnosed before 30 years of age. Diabetes Care 8(Suppl. 1), 71-76 (1985).
93. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91(12), 1464-1474 (1984).
94. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology 99(1), 58-62 (1992).
95. Klein R, Palta M, Allen C, Shen G, Han DP, D'Alessio DJ. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch. Ophthalmol. 115(3), 351-356 (1997).
96. Kostraba JN, Klein R, Dorman JS et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am. J. Epidemiol. 133(4), 381-391 (1991).
97. Leske MC, Wu SY, Hyman L et al. Diabetic retinopathy in a black population: the Barbados Eye Study. Ophthalmology 106(10), 1893-1899 (1999).
98. Roy MS. Diabetic retinopathy in African - Americans with Type 1 diabetes: the New Jersey 725: I. Methodology, population, frequency of retinopathy, and visual impairment. Arch. Ophthalmol. 118(1), 97-104 (2000).
99. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult Type 1 diabetic persons in the United States. Arch. Ophthalmol. 122(4), 546-551 (2004).
100. Varma R, Torres M, Pena F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology 111(7), 1298-1306 (2004).
101. Broadbent DM, Scott JA, Vora JP, Harding SP. Prevalence of diabetic eye disease in an inner city population: the Liverpool Diabetic Eye Study. Eye 13(Pt 2), 160-165 (1999).
102. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye 16(2), 140-145 (2002).
103. McLeod BK, Thompson JR, Rosenthal AR. The prevalence of retinopathy in the insulin-requiring diabetic patients of an English country town. Eye 2(Pt 4), 424-430 (1988).
104. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR. The prevalence of multiple diabetes-related complications. Diabet. Med. 17(2), 146-151 (2000).
105. UKPDS Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes 44, 1249-1258 (1995).
106. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37(3), 278-285 (1994).
107. Agardh E, Torffvit O, Agardh CD. The prevalence of retinopathy and associated medical risk factors in Type I (insulin-dependent) diabetes mellitus. J. Intern. Med. 226(1), 47-52 (1989).
108. Bognetti E, Calori G, Meschi F, Macellaro P, Bonfanti R, Chiumello G. Prevalence and correlations of early microvascular complications in young Type I diabetic patients: role of puberty. J. Pediatr. Endocrinol. Metab. 10(6), 587-592 (1997).
109. Cahill M, Halley A, Codd M et al. Prevalence of diabetic retinopathy in patients with diabetes mellitus diagnosed after the age of 70 years. Br. J. Ophthalmol. 81(3), 218-222 (1997).
110. Danielsen R, Jonasson F, Helgason T. Prevalence of retinopathy and proteinuria in Type 1 diabetics in Iceland. Acta Med. Scand. 212(5), 277-280 (1982).
111. De Pablos PL, Martinez J, Martinez MP, Doreste JA. Prevalence of micro- and macroalbuminuria in a Canarian population of Type 2 diabetic patients. Relationship with blood pressure, lipid profile, obesity and metabolic control. Diabetes Metab. 24(4), 337-343 (1998).
112. Delcourt C, Vauzelle-Kervroedan F, Cathelineau G, Papoz L; CODIAB-INSERM-ZENECA Pharma Study Group. Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study. J. Diabetes Complicat. 12(2), 88-95 (1998).
113. Ebeling P, Koivisto VA. Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland. Acta Diabetol. 34(1), 33-38 (1997).
114. Falkenberg M, Finnstrom K. Associations with retinopathy in Type 2 diabetes: a population-based study in a Swedish rural area. Diabet. Med. 11(9), 843-849 (1994).
115. Fernandez-Vigo J, Sanchez MJ, Diaz RA, Barros J, Tome M, Bueno J. The prevalence of diabetic retinopathy in northwest Spain. An epidemiological study of diabetic retinopathy in Galicia. I. Acta Ophthalmol. (Copenh.) 71(1), 22-26 (1993).
116. Garancini P, Micossi P, Valsania P et al. Prevalence of retinopathy in diabetic subjects from out-patient clinics in Lombardy (Italy), and associated risk factors. A multicentre epidemiologic study. Diabetes Res. Clin. Pract. 6(2), 129-138 (1989).
117. Hapnes R, Bergrem H. Diabetic eye complications in a medium sized municipality in southwest Norway. Acta Ophthalmol. Scand. 74(5), 497-500 (1996).
118. Haupt E, Benecke A, Haupt A, Herrmann R, Vogel H, Walter C. The KID Study VI: diabetic complications and associated diseases in younger Type 2 diabetics still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. Exp. Clin. Endocrinol. Diabetes 107(7), 435-441 (1999).
119. Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol. Scand. 74(6), 523-527 (1996).
120. Hirvela H, Laatikainen L. Diabetic retinopathy in people aged 70 years or older. The Oulu Eye Study. Br. J. Ophthalmol. 81(3), 214-217 (1997).
121. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of Type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol. Scand. 82(4), 443-448 (2004).
122. Jerneld B, Algvere P. Prevalence of retinopathy in diabetes treated with oral antihyperglycaemic agents. Acta Ophthalmol. (Copenh.) 63(5), 535-540 (1985).
123. Jerneld B, Algvere P. Relationship of duration and onset of diabetes to prevalence of diabetic retinopathy. Am. J. Ophthalmol. 102(4), 431-437 (1986).
124. Kravchenko VI, Tronko ND, Pankiv VI, Venzilovich Y, Prudius FG. Prevalence of diabetes mellitus and its complications in the Ukraine. Diabetes Res. Clin. Pract. 34(Suppl.), S73-S78 (1996).
125. Kuiv R, Tein P, Algvere PV, Backlund LB, Holm O. Photographic detection of retinopathy in insulin-treated diabetes. A population study in the city of Tartu, Estonia. Acta Ophthalmol. Scand. 75(4), 447-456 (1997).
126. Lopez IM, Diez A, Velilla S, Rueda A, Alvarez A, Pastor CJ. Prevalence of diabetic retinopathy and eye care in a rural area of Spain. Ophthalmic Epidemiol. 9(3), 205-214 (2002).
127. Lundman B, Engstrom L. Diabetes and its complications in a Swedish county. Diabetes Res. Clin. Pract. 39(2), 157-164 (1998).
128. Olsen BS, Johannesen J, Sjolie AK et al.; Danish Study Group of Diabetes in Childhood. Metabolic control and prevalence of microvascular complications in young Danish patients with Type 1 diabetes mellitus. Diabet. Med. 16(1), 79-85 (1999).
129. Pinto-Figueiredo L, Moita J, Genro V et al. Diabetic retinopathy in a population of 1,302 insulin dependent diabetics (IDDM) diagnosed before 30 years of age. Int. Ophthalmol. 16(6), 429-437 (1992).
130. Pisu E, Vitelli F, Coggi G et al. Univariate and multivariate analysis of associated factors of retinopathy in 894 Italian adult diabetics. Diabetes Metab. 14(6), 700-705 (1988).
131. Reuterving CO, Kratholm J, Wachtmeister L. Ophthalmic health care in diabetes mellitus: a cross-sectional study in northern Sweden. Ophthalmic Epidemiol. 6(4), 267-278 (1999).
132. Segato T, Midena E, Grigoletto F et al. The epidemiology and prevalence of diabetic retinopathy in the Veneto region of north east Italy. Veneto Group for Diabetic Retinopathy. Diabet. Med. 8 Spec. No., S11-S16 (1991).
133. Sjolie AK, Stephenson J, Aldington S et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104(2), 252-260 (1997).
134. Verhoeven S, van Ballegooie E, Casparie AF. Impact of late complications in Type 2 diabetes in a Dutch population. Diabet. Med. 8(5), 435-438 (1991).
135. Jaross N, Ryan P, Newland H. Prevalence of diabetic retinopathy in an Aboriginal Australian population: results from the Katherine Region Diabetic Retinopathy Study (KRDRS). Report no. 1. Clin. Experiment. Ophthalmol. 31(1), 32-39 (2003).
136. McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project. Br. J. Ophthalmol. 84(8), 865-870 (2000).
137. Mitchell P. Development and progression of diabetic eye disease in Newcastle (1977-1984): rates and risk factors. Aust. N. Z. J. Ophthalmol. 13(1), 39-44 (1985).
138. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 105(3), 406-411 (1998).
139. Tapp RJ, Shaw JE, Harper CA et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 26(6), 1731-1737 (2003).
140. Choremis J, Chow DR. Use of telemedicine in screening for diabetic retinopathy. Can. J. Ophthalmol. 38(7), 575-579 (2003).
141. Hanley AJ, Harris SB, Mamakeesick M et al. Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. Diabetes Care 28(8), 2054-2057 (2005).
142. Maberley D, Cruess AF, Barile G, Slakter J. Digital photographic screening for diabetic retinopathy in the James Bay Cree. Ophthalmic Epidemiol. 9(3), 169-178 (2002).
143. Tennant MT, Greve MD, Rudnisky CJ, Hillson TR, Hinz BJ. Identification of diabetic retinopathy by stereoscopic digital imaging via teleophthalmology: a comparison to slide film. Can. J. Ophthalmol. 36(4), 187-196 (2001).
144. Tennant MT, Rudnisky CJ, Hinz BJ, MacDonald IM, Greve MD. Tele-ophthalmology via stereoscopic digital imaging: a pilot project. Diabetes Technol. Ther. 2(4), 583-587 (2000).
145. Sparrow JM, McLeod BK, Smith TD, Birch MK, Rosenthal AR. The prevalence of diabetic retinopathy and maculopathy and their risk factors in the non-insulin-treated diabetic patients of an English town. Eye 7(Pt 1), 158-163 (1993).
146. Arfken CL, Salicrup AE, Meuer SM et al. Retinopathy in African Americans and whites with insulin-dependent diabetes mellitus. Arch. Intern. Med. 154(22), 2597-2602 (1994).
147. Dwyer MS, Melton LJ 3rd, Ballard DJ, Palumbo PJ, Trautmann JC, Chu CP. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 8(4), 316-322 (1985).
148. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am. J. Kidney Dis. 31(6), 947-953 (1998).
149. Klein BE, Davis MD, Segal P et al. Diabetic retinopathy. Assessment of severity and progression. Ophthalmology 91(1), 10-17 (1984).
150. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 96(10), 1501-1510 (1989).
151. Lee ET, Lee VS, Kingsley RM et al. Diabetic retinopathy in Oklahoma Indians with NIDDM. Incidence and risk factors. Diabetes Care 15(11), 1620-1627 (1992).
152. Nelson RG, Wolfe JA, Horton MB, Pettitt DJ, Bennett PH, Knowler WC. Proliferative retinopathy in NIDDM. Incidence and risk factors in Pima Indians. Diabetes 38(4), 435-440 (1989).
153. Tudor SM, Hamman RF, Baron A, Johnson DW, Shetterly SM. Incidence and progression of diabetic retinopathy in Hispanics and non-Hispanic whites with Type 2 diabetes. San Luis Valley Diabetes Study, Colorado. Diabetes Care 21(1), 53-61 (1998).
154. Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in Type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res. Clin. Pract. 35(2-3), 113-121 (1997).
155. Agardh E, Agardh CD, Koul S, Torffvit O. A four-year follow-up study on the incidence of diabetic retinopathy in older onset diabetes mellitus. Diabet. Med. 11(3), 273-278 (1994).
156. Guillausseau PJ, Massin P, Charles MA et al. Glycaemic control and development of retinopathy in Type 2 diabetes mellitus: a longitudinal study. Diabet. Med. 15(2), 151-155 (1998).
157. Nielsen NV. Diabetic retinopathy I. The course of retinopathy in insulin-treated diabetics. A one year epidemiological cohort study of diabetes mellitus. The Island of Falster, Denmark. Acta Ophthalmol. (Copenh.) 62(2), 256-265 (1984).
158. Rossing K, Jacobsen P, Rossing P, Lauritzen E, Lund-Andersen H, Parving HH. Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. Diabetes Care 21(11), 2007-2015 (1998).
159. Cohen DL, Neil HA, Thorogood M, Mann JI. A population-based study of the incidence of complications associated with Type 2 diabetes in the elderly. Diabet. Med. 8(10), 928-933 (1991).
160. Jaross N, Ryan P, Newland H. Incidence and progression of diabetic retinopathy in an Aboriginal Australian population: results from the Katherine Region Diabetic Retinopathy Study (KRDRS). Report no. 2. Clin. Experiment. Ophthalmol. 33(1), 26-33 (2005).
161. McCarty DJ, Fu CL, Harper CA, Taylor HR, McCarty CA. Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project. Clin. Experiment. Ophthalmol. 31(5), 397-402 (2003).
162. Mitchell P, Moffitt P. Update and implications from the Newcastle diabetic retinopathy study. Aust. N. Z. J. Ophthalmol. 18(1), 13-17 (1990).
163. Chaturvedi N, Sjoelie AK, Porta M et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in Type 1 diabetes. Diabetes Care 24(2), 284-289 (2001).
164. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology 95(10), 1340-1348 (1988).
165. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101(6), 1061-1070 (1994).
166. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105(6), 998-1003 (1998).
167. Henricsson M, Tyrberg M, Heijl A, Janzon L. Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmol. Scand. 74(6), 533-538 (1996).
168. Jeppesen P, Bek T. The occurrence and causes of registered blindness in diabetes patients in Arhus County, Denmark. Acta Ophthalmol. Scand. 82(5), 526-530 (2004).
169. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J. Diabetes Complicat. 15(6), 287-294 (2001).
170. Voutilainen-Kaunisto R, Terasvirta M, Uusitupa M, Niskanen L. Maculopathy and visual acuity in newly diagnosed Type 2 diabetic patients and non-diabetic subjects: a 10-year follow-up study. Acta Ophthalmol. Scand. 79(2), 163-168 (2001).
171. Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, Niskanen LK. Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J. Diabetes Complicat. 15(1), 24-33 (2001).
172. Arun CS, Ngugi N, Lovelock L, Taylor R. Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet. Med. 20(3), 186-190 (2003).
173. Cormack TG, Grant B, Macdonald MJ, Steel J, Campbell IW. Incidence of blindness due to diabetic eye disease in Fife 1990-1999. Br. J. Ophthalmol. 85(3), 354-356 (2001).
174. Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. Eye 15(Pt 5), 640-643 (2001).
175. McKay R, McCarty CA, Taylor HR. Diabetes in Victoria, Australia: the Visual Impairment Project. Aust. NZ J. Public Health 24(6), 565-569 (2000).